Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
The Journal of General Virology|January 15, 2009
Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in miceNina Wressnigg, Anna Polina Shurygina, Thorsten Wolff, et al.Archives of Virology|July 29, 2015
A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in miceChristian Kittel, Nina Wressnigg, Anna Polina Shurygina, et al.Vaccine|July 18, 2026
Ethical challenges in outbreak trial design: from Ebola to NipahEuzebiusz Jamrozik, Lucie Abeler-Dörner, Amol Chaudhari, et al.Biotechnology Journal|December 11, 2013
Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccinesSabine Nakowitsch, Andrea M Waltenberger, Nina Wressnigg, et al.Vaccine|April 16, 2009
Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidateNina Wressnigg, Daniel Voss, Thorsten Wolff, et al.The Lancet. Infectious Diseases|July 7, 2023
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adultsNicole Bézay, Romana Hochreiter, Vera Kadlecek, et al.The Lancet. Infectious Diseases|June 3, 2024
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studiesNicole Bézay, Laura Wagner, Vera Kadlecek, et al.JCI Insight|June 14, 2022
Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human seraPierre Roques, Andrea Fritzer, Nathalie Dereuddre-Bosquet, et al.Clinical and Vaccine Immunology : CVI|December 26, 2014
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trialNina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, et al.Journal of Travel Medicine|December 13, 2023
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†Robert McMahon, Ulrike Fuchs, Martina Schneider, et al.Pageof 2